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INTRODUCTION
Radiofrequency catheter ablation (RFCA) has been shown to 
effectively reduce the burden of atrial fibrillation (AF).1,2 Since 
Haïssaguerre, et al.3 reported focal ablation of pulmonary vein 
(PV) triggers by single ablation catheter after single trans-sep-
tal puncture in 1998, the indications for RFCA have been ex-
panded in light of accumulating clinical experience and evi-
dence.4 Circumferential pulmonary vein isolation (CPVI) 
remains the cornerstone of AF ablation,5,6 and current technol-
ogies, such as irrigated tip ablation catheters,7 contact force 
technology,8 and three-dimensional (3D) electroanatomical 
mapping with software monitoring for catheter stability,9 have 
allowed for efficient and long-lasting CPVI, as well as improved 
rhythm outcomes, in AF catheter ablation. For CPVI, most op-
erators place two long sheaths across the interatrial septum, 
one for a PV mapping catheter and the other for the ablation 
catheter. In this double trans-septal (DT) method, CPVI is per-
formed while watching PV potentials. This technique requires 
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bilateral groin (BG) puncture and a relatively long post-proce-
dural hemostasis time, with both lower extremities remaining 
extended after the procedure. Indeed, the long duration of 
post-procedural immobilization for hemostasis can cause 
back pain, discomfort, negative immunomodulatory effects,10 
and bleeding complications. In addition, Asian patients are 
known to be vulnerable to bleeding under anticoagulation.11 
Recently, commercialized cryoballoon PV ablation was found 
to result in clinical outcomes comparable to RFCA by a unilat-
eral groin (UG) puncture,12 and the invasiveness of the proce-
dure became an important issue. In the present study, we hy-
pothesized that UG puncture-single trans-septal (ST) CPVI 
would be feasible and safe and would reduce patient post-
procedural discomfort during hemostasis after RFCA for par-
oxysmal AF, as the patient has one leg that is free to move after 
the UG-ST procedure, compared to the BG-DT approach. The 
purpose of this study was to compare rates of procedural suc-
cess and complications, as well as post-procedural patient sat-
isfaction and rhythm outcomes, between UG-ST and BG-DT 
CPVIs via a multi-center prospective randomized trial design. 
MATERIALS AND METHODS
Study population 
The study protocol was approved by the institutional review 
boards of the participating hospitals (ClinicalTrials.gov Iden-
tifier: NCT02438176). The study received ethics committee 
approval from each hospital [The Institutional Review Board 
of Severance Cardiovascular Hospital (IRB: 4-2015-0170), The 
Institutional Review Board of Korea University Cardiovascular 
Center, The Institutional Review Board of Asan Medical Center] 
and complied with the Declaration of Helsinki. All participants 
provided written informed consent. We originally planned to 
recruit 70 patients in the UG-ST group and 35 patients in the 
BG-DT group, however, we recruited additional participants 
to further improve the statistical power of the study under the 
approval of the ethics committee. Finally, from April 2015 to 
June 2017, a total of 222 patients with anti-arrhythmic drug 
(AAD) refractory symptomatic paroxysmal AF were enrolled 
in this prospective, randomized, single blind study performed 
at three tertiary hospitals in Seoul, Korea. Paroxysmal AF was 
defined as a history of ≥one episode of self-terminating AF 
lasting ≤7 days. Exclusion criteria consisted of not agreeing to 
enroll in the study, persistent AF, difficulty in performing a 
single groin puncture due to vascular disease or venous 
anomaly, history of previous RFCA or cardiac surgery, and 
valvular or structural heart disease other than left ventricular 
hypertrophy. Patients were randomly assigned to the UG-ST 
or BG-DT groups using a table of random numbers in a 2:1 ra-
tio (Fig. 1). In the case of failed PV isolation despite three at-
tempts at touch-up ablation in the UG-ST group, the patient 
was crossed over to BG-DT. All AADs were withheld for >5 
half-lives before the procedure. All patients received at least 3 
weeks of non-vitamin K antagonist oral anticoagulant (NOAC) 
prior to the procedure.13 Prior to ablation, all patients under-
went 64-channel multi-detector computed tomography (CT), 
and pre-procedural transesophageal echocardiogram was 
evaluated in patients with CHA2DS2-VASc scores ≥2, suspicious 
left atrial appendage thrombus on CT, or potential for poor 
adherence to anticoagulation therapy. 
Groin puncture and catheter setting
Procedures were performed under conscious sedation/anal-
gesia. For the BG-DT group (Fig. 2A), a 14-Fr venous tripod 
sheath was introduced to the left femoral vein (for duodecap-
olar, decapolar, and quardripolar catheters), and a 6-Fr arteri-
al locking sheath was introduced into the left femoral artery 
(for reference catheter and blood pressure monitoring), re-
spectively. Two long trans-septal sheaths (Schwartz left-1, 
Patients with anti-arrhythmia drug
refractory symptomatic paroxysmal  
atrial fibrillation (n=222)
2:1 randomization
UG-ST group BG-DT group
Procedure related analysis (n=138) Procedure related analysis (n=74)
Full analysis (n=148) 
Crossover to alternative access (n=10)
Full analysis (n=74)
Fig. 1. Flow diagram of study population enrollment. UG-ST, unilateral groin puncture-single trans-septal; BG-DT, bilateral groin puncture-double trans-septal.
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braided, 8-Fr, Abbott Inc., Minnetonka, MN, USA) were then 
introduced into the right femoral vein (for an ablation catheter 
and a PV mapping catheter). 
In the UG-ST group, we placed a 14-Fr tripod sheath and a 
trans-septal long sheath into the right femoral vein, and a 6-Fr 
artery sheath into the right femoral artery; there was no left 
side groin access (Fig. 2B). We introduced the same catheters 
used in the BG-DT group through three vascular sheaths; how-
ever, the ablation and PV mapping catheters shared a long 
sheath. 
Electrophysiological mapping and ablation
Intracardiac electrograms were recorded using the Prucka Car-
dioLabTM Electrophysiology system (General Electric Medical 
Systems, Inc., Milwaukee, WI, USA). RFCA was performed in 
all patients using 3D electroanatomical mapping (NavX, Ab-
bott Inc.) merged with 3D spiral CT. After obtaining multiview 
pulmonary venograms and securing trans-septal access, the 
3D geometries of both the LA and PV were obtained using a 
3D-electroanatomical mapping system (NavX, Abbott Inc.), 
which were then merged with 3D spiral CT images. Systemic 
anticoagulation was performed with intravenous heparin to 
maintain an activated clotting time of 350–400 seconds dur-
ing the procedure. Details on the RFCA technique and the 
strategy used in the current study have been described previ-
ously by our group.14 Briefly, an open irrigated-tip catheter 
(Coolflex, Abbott Inc.; Thermocool, Johnson & Johnson Inc., 
Diamond Bar, CA, USA; 25–35 W; irrigation rate of 10–15 mL/
min, continuous and endurance ablation with staying 30 sec-
onds in each ablation point) was used to deliver RF energy for 
ablation. All patients underwent CPVI and cavo-tricuspid 
isthmus (CTI) ablation. Successful CPVI was defined as elimi-
nation of all PV potentials along the antrum and inside the 
vein. Bidirectional CTI block was confirmed by differential 
pacing.
In the UG-ST group, we exchanged he ablation catheter 
with a PV mapping catheter after circumferential PV ablation, 
localized the remaining entrance site of PV potentials with 
quick 3D mapping (NavX, Abbott Inc.) (Fig. 2C), and achieved 
PV isolation by touch-up ablation. If we failed to isolate four 
PVs after three attempts at repeated touch-up ablation, we 
conducted left groin puncture and additional trans-septal 
puncture, and isolated four PVs during simultaneous PV po-
tential monitoring by PV mapping catheter (cross over to the 
BG-DT protocol). As a final step, mappable AF triggers or atrial 
premature beats seen with isoproterenol infusion (5 µg/min) 
were carefully mapped and the corresponding non-PV foci 
were ablated as much as possible.15 
Hemostasis and questionnaire 
After sheath removal, manual compression was applied to the 
puncture sites until hemostasis was achieved. After 4 hours of 
immobilization, the puncture sites were inspected. In the BG-
DT group, patients were asked not to flex either lower extremi-
ty, and immobilization was maintained overnight. In contrast, 
patients in the UG-ST group were allowed to move their left leg 
(opposite to the groin puncture side) and short distance am-
bulation after 6 hours of stabilization. Major hematoma was 
defined as bleeding or a significantly visible hematoma of the 
groin site when the hospital discharge was delayed by more 
than one day. A NOAC was restarted on the day of the procedure 
after confirming hemostasis. Oral anticoagulation was contin-
ued for at least 2 months after the procedure in all patients. 
A questionnaire covering subjective discomfort during he-
BA CBG-DT UG-ST
Fig. 2. Representative images of conventional bilateral groin puncture-double trans-septal ablation (BG-DT) (A) and unilateral groin puncture-single 
trans-septal ablation (UG-ST) (B) strategies. If there was a remnant PV potential after anatomical and local potential guided CPVI in the UG-ST group, we 
mapped and marked the potential PV conduction site on a three-dimensional electroanatomical map and added tough-up ablation after an additional ex-
change of ablation and mapping catheters (C). CPVI, circumferential pulmonary vein isolation; PV, pulmonary vein; RA, right atrium; RV, right ventricle; CS, 
coronary sinus; LAO, left anterior oblique.
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mostasis was provided to patients one day after the procedure, 
prior to hospital discharge, with standardized instructions in 
accordance with previously published guidelines.16 The ques-
tionnaire, which was completed by the patients, consisted of a 
visual analog scale (VAS) of 0 to 10 covering overall discomfort, 
access site pain, back pain, ability to use the restroom, ability 
to eat and perform self-care, and walking (Supplementary Fig. 
1, only online). The total VAS score was calculated by summa-
tion of VAS scores from each category. 
Follow-up after procedure
According to standard RFCA procedures, AADs were discontin-
ued in the majority of patients, but continued in 6.8% (15/222) 
of patients with a high chance of early recurrence or symptom-
atic atrial arrhythmias at discharge. All patients were sched-
uled for outpatient clinic follow up at 1, 3, 6, and 12 months, 
and every 6 months thereafter or upon becoming symptom-
atic. Rhythm follow ups were performed at every visit by ECG, 
and a 24-hour Holter monitoring and/or event recording was 
conducted at 3- and 6-month intervals during the first year 
and every six months thereafter according to the 2012 Heart 
Rhythm Society/European Heart Rhythm Society/European 
Cardiac Arrhythmia Society Expert Consensus Statement guide-
lines.17 Additionally, if a patient presented with palpitations, 
Holter monitoring or event recording was used to screen for 
arrhythmias. We defined recurrence of AF as any episode of AF 
or atrial tachycardia lasting longer than 30 seconds. Early re-
currence was defined as any episode of recurrent AF occurring 
within 3 months of the blanking period. Any ECG documenta-
tion of AF recurrence after the blanking period was diagnosed 
as clinical recurrence. The primary outcomes consisted of CPVI 
success rate, procedure time, and peri-procedural complica-
tion rates within 30 days of the procedure, including groin site 
complications. The secondary outcomes were VAS score for 
discomfort during hemostasis and clinical recurrence rates of 
atrial arrhythmias. 
Statistical analysis
We established treatment superiority based on VAS according 
to a previous patient satisfaction study. Specifically, a decrease 
in VAS score >33% was considered to represent an increase in 
patient satisfaction.18 A statistical power of 80% and a two-
tailed type 1 error of 5% was used to identify significant differ-
ences, considering a potential dropout rate of 10%. Patients 
were assigned in a 2:1 ratio out of consideration for the possi-
bility of procedure crossover, such as from a UG to bilateral 
approach, and a total of 222 patients was enrolled in the study 
(UG-ST group 148 patients and BG-DT group 74 patients). 
Continuous variables are reported as mean±standard devia-
tion and were analyzed using Student’s t-test or the Mann-
Whitney U test as appropriate. Normality was determined us-
ing the Kolmogorov-Smirnov goodness-of-fit test. Categorical 
variables are reported as counts and proportions, and were an-
alyzed using Pearson’s chi-square test or Fisher’s exact test as 
appropriate. Kaplan-Meier analyses with log rank tests were 
used to compare AF recurrence-free survival over time be-
tween the two groups. Statistical analysis was performed us-
ing SPSS (version 23.0, IBM Corp., Armonk, NY, USA) software 
for Windows. A p-value <0.05 was considered statistically sig-
nificant. 
RESULTS
Baseline characteristics
A total of 222 patients were enrolled in the study and were ran-
domized to the UG-ST group and BG-DT groups in 2:1 man-
ner, with 148 patients in the UG-ST group and 74 patients in the 
in the BG-DT group. The mean patient age was 59.4±10.7 years, 
and 154 (69.4%) patients were male. The mean CHA2DS2-VASc 
score was 1.8±1.6. The two groups were balanced in regards 
to baseline characteristics after randomization as shown in 
Table 1. 
Acute procedural outcomes
Bidirectional block of CPVI and CTI ablation was successfully 
achieved in all patients of both groups. Among the 148 patients 
in the UG-ST group, 10 (6.8%) required procedure crossover 
with additional left groin puncture and trans-septal puncture 
due to difficulty in achieving CPVI after three trials of touch-up 
Table 1. Baseline Clinical Characteristics
Overall
(n=222)
UG-ST 
group
(n=148)
BG-DT 
group
(n=74)
p value
Age (yr) 59.4±10.7 58.7±11.0 60.9±10.0 0.149
Male sex 154 (69.4) 108 (73.0) 46 (62.2) 0.100
BMI (kg/m2) 25.0±3.3 25.1±3.4 24.7±3.1 0.383
Comorbidities
Heart failure 18 (8.1) 12 (8.1) 6 (8.1) >0.999
Hypertension 101 (45.5) 66 (44.6) 35 (47.3) 0.703
Diabetes mellitus 41 (18.5) 25 (16.9) 16 (21.6) 0.392
Stroke or TIA 28 (12.6) 18 (12.2) 10 (13.5) 0.775
Vascular disease 26 (11.7) 17 (11.5) 9 (12.2) 0.883
CHA2DS2-VASc score 1.8±1.6 1.7±1.6 1.9±1.5 0.381
Echocardiography
LA diameter (mm) 39.5±5.7 39.7±6.1 39.2±4.8 0.543
LAVI (mL/m2) 34.7±12.5 35.3±13.5 33.6±10.3 0.357
LVEF (%) 64.7±7.3 64.2±7.7 65.6±6.4 0.166
E/Em 9.9±3.9 10.1±4.0 9.6±3.5 0.370
LVEDD (mm) 49.7±4.0 49.8±4.2 49.6±3.6 0.810
UG-ST, unilateral groin puncture-single trans-septal; BG-DT, bilateral groin punc-
ture-double trans-septal; BMI, body mass index; TIA, transient ischemic attack; 
LA, left atrium; LAVI, LA volume index; LVEF, LV ejection fraction; E/Em, early mi-
tral inflow velocity to early diastolic mitral annular velocity ratio; LVEDD, left 
ventricular end diastolic dimension.
Variables are presented as mean±standard deviation or count (percentage). 
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ablation. The 10 crossover subjects were all male, had no co-
morbidities other than hypertension, and had lower CHA2DS2-
VASc score (0.9±0.7 vs. 1.8±1.7, p=0.005) than the remainder 
of patients in the UG-ST group (Supplementary Table 1, only 
online). Their other characteristics, such as echocardiograph-
ic parameters or procedure time, ablation time, and fluoro-
scopic time, were not significantly different from the remain-
der of patients in the UG-ST group. Table 2 summarizes the 
acute procedural outcomes of this study. Total procedure time 
(p=0.144), ablation time (p=0.248), and fluoroscopic time (p= 
0.717) were not significantly different between the two groups. 
The overall procedure-related complication rate was 5.4% 
(12/222). There were no significant differences in major com-
plication rate (2.0% vs. 2.7%, p>0.999), including cardiac tam-
ponade (1.4% vs. 2.7%, p=0.602) and atrioesophageal fistula 
(0.7% vs. 0%, p>0.999), between the two groups. Likewise, there 
were no instances of stroke or transient ischemic attack after 
RFCA in either group. Minor vascular complications, includ-
ing femoral arteriovenous fistula not requiring surgical treat-
ment or transfusion, and thigh hematoma occurred less fre-
quently in the UG-ST group than in the BG-DT group (1.4% vs. 
6.8%, p=0.043). In addition, after excluding the 10 patients in 
the UG-ST group who were crossed-over to the double trans-
septal puncture, acute procedural outcome and major compli-
cation rates were consistent with those in the BG-DT group 
(Supplementary Table 1, only online). There were no proce-
dure-related complications in the 10 crossover patients either.
Post-procedural discomfort during hemostasis 
A questionnaire for post-procedural discomfort during hemo-
stasis was successfully administered according to guidelines 
in 97.8% (135/138) of patients in the UG-ST group after ex-
cluding the 10 crossover patients and in 98.6% (73 of 74) pa-
tients in the BG-DT group. According to the patient satisfaction 
survey, total VAS score (p=0.015), access site pain score (p= 
0.014), and back pain score (p=0.023) were significantly lower 
in the UG-ST group than in the BG-DT group (Fig. 3). 
Table 2. Procedure Related Characteristics
Overall (n=222) UG-ST group (n=148) BG-DT group (n=74) p value
Procedure time (min) 184.0±37.2 186.6±37.0 178.8±37.3 0.144
Ablation time (sec) 4722.3±936.2 4773.8±938.8 4619.4±928.8 0.248
Fluoroscopy time (min) 34.8±12.3 34.6±12.2 35.2±12.5 0.717
Major complications 5 (2.3) 3 (2.0) 2 (2.7) >0.999
Cardiac tamponade 4 (1.8) 2 (1.4) 2 (2.7) 0.602
AE fistula 1 (0.5) 1 (0.7) 0 (0) >0.999
Stroke or TIA 0 (0) 0 (0) 0 (0) >0.999
Minor vascular complications 7 (3.2) 2 (1.4) 5 (6.8) 0.043
Femoral AV fistula 3 (1.4) 1 (0.7) 2 (2.7) 0.258
Femoral pseudoaneurysm 0 (0) 0 (0) 0 (0) >0.999
Thigh hematoma 4 (1.8) 1 (0.7) 3 (4.1) 0.109
UG-ST, unilateral groin puncture-single trans-septal; BG-DT, bilateral groin puncture-double trans-septal; AE, atrioesophageal; TIA, transient ischemic attack; AV, 
arteriovenous.
Variables are presented as mean±standard deviation or count (percentage).
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Fig. 3. Comparison of questionnaire results for post-procedural discomfort during hemostasis between the two groups. (A) Each component of quality 
of life was measured using a 0–10 VAS. (B) Total score of VAS results. UG-ST, unilateral groin puncture-single trans-septal; BG-DT, bilateral groin punc-
ture-double trans-septal; VAS, visual analog scale.
365
Hee Tae Yu, et al.
https://doi.org/10.3349/ymj.2019.60.4.360
Clinical rhythm outcomes
Table 3 shows the clinical rhythm outcomes of the study 
groups. During 20.2±8.7 months of follow up, there was clinical 
recurrence in 16 patients in the UG-ST group and 8 patients in 
the BG-DT group (10.8% vs. 10.8%, p>0.999). After excluding 
the 10 crossover patients of the UG-ST group, the rate of clini-
cal recurrence was 10.9% (15/138). The rate of early recurrence 
was not different between the UG-ST and BG-DT groups 
(p=0.541). Overall, Kaplan-Meier analyses showed compara-
ble rhythm outcomes in the UG-ST group, compared to the 
BG-DT group (Log rank p=0.984) (Fig. 4A), as well as after ex-
cluding patients being treated with an AAD (Log rank p=0.976) 
(Fig. 4B). 
DISCUSSION
In this multicenter prospective randomized study for compari-
son of a unilateral groin puncture procedure with that of con-
ventional bilateral groin puncture, UG-ST was a feasible and 
safe ablation strategy for CPVI, even though it was a single 
trans-septal procedure. Moreover, the UG-ST method reduced 
post-procedural discomfort significantly during hemostasis, 
and the rate of clinical recurrence of AF was comparable to 
that of conventional bilateral groin puncture with the double 
trans-septal method (BG-DT group). 
There is a general consensus that CPVI is the cornerstone of 
AF catheter ablation in both paroxysmal AF and persistent 
AF.2,19 Although a reconnected PV potential is known to be the 
main mechanism of AF recurrence,14 achieving long-term PV 
isolation has increased significantly with technological advanc-
es in ablation catheters, mapping, and imaging technology.7-9 
The central hypothesis of this study was that successful CPVI 
could be achieved by a sophisticated ST-single catheter antral 
ablation without continuous PV potential monitoring by a PV 
mapping catheter, which requires DT access. While it is incon-
venient for operators to switch between the ablation catheter 
and PV mapping catheter through a single trans-septal sheath, 
UG-ST ablation successfully achieved CPVI in the majority of 
patients (93.2%) without worsening of procedure times, com-
plication rates, or clinical outcomes. 
AF ablation is a complex procedure that requires multiple 
catheter mappings, a relatively long procedure time, intra-pro-
cedural heavy anticoagulation, and uninterrupted peri-proce-
dural anticoagulation.20 Therefore, complications associated 
with vascular access are relatively common: groin hematoma, 
retroperitoneal hematoma, femoral pseudoaneurysm, femo-
ral arteriovenous fistula, and hemo- or pneumothorax.21-23 To 
reduce the number of vascular access sites, such as subclavian 
or internal jugular venous access, we have been using a bilat-
eral groin puncture method.24,25 In this study, we further simpli-
fied vascular access in the UG-ST method, similar to the gener-
alized setting when performing cryoballoon ablation.26 The 
UG-ST method significantly reduced patient discomfort dur-
ing hemostasis, because it allowed the patients to move their 
left side lower extremity. 
There has been only one study to date that has reported on 
patient satisfaction during and immediately after AF ablation 
procedures, and dissatisfaction mainly occurs due to excess 
pain during and after ablation.27 Taking into account both the 
procedure time and hemostatic time, patients undergoing AF 
Table 3. Clinical Rhythm Outcomes 
Overall
(n=222)
UG-ST 
group
(n=148)
BG-DT 
group
(n=74)
p value
Post ablation AAD use at 
3 months
15 (6.8) 8 (5.4) 7 (9.5) 0.257
Follow up (month) 20.2±8.7 20.4±9.0 19.6±8.1 0.481
Early recurrence 41 (18.5) 29 (19.6) 12 (16.2) 0.541
Clinical recurrence 24 (10.8) 16 (10.8) 8 (10.8) >0.999
UG-ST, unilateral groin puncture-single trans-septal; BG-DT, bilateral groin punc-
ture-double trans-septal; AAD, anti-arrhythmic drug.
Variables are presented as mean±standard deviation or count (percentage).
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Fig. 4. Kaplan-Meier analysis of AF recurrence-free survival (A) and AF recurrence-free survival off-AAD (B) after catheter ablation between the two 
groups. AF, atrial fibrillation; AAD, anti-arrhythmic drug; UG-ST, unilateral groin puncture-single trans-septal; BG-DT, bilateral groin puncture-double 
trans-septal.
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catheter ablation must remain in a supine position for at least 
8 hours, which is both uncomfortable and difficult, especially 
in older adult patients with back pain. We proved that the UG-
ST method is valuable to improve satisfaction of patients who 
undergo AF catheter ablation in this study. 
Although PV stenosis is uncommon after antral CPVI, it can 
occur after deeper and massive ablations.28 In cases of a rem-
nant PV potential after initial CPVI by SG-ST single catheter 
ablation, we strongly recommend the use of quick 3D-activa-
tion mapping, as shown in Fig. 2C, before touch-up ablation. 
This method is not only very efficient to eliminate PV poten-
tial with minimal RF energy delivery, but also effective in pre-
venting the temptation to ablate in PV inside. In order to avoid 
this complication, patients being treated by the UG-ST meth-
od were crossed over to the BG-DT method, if three touch-up 
ablations failed to achieve secure CPVI. Another potential com-
plication of the UG-ST method is air-embolism during repeat-
ed exchange of the ablation catheter and PV mapping cathe-
ter.29 Although none of the patients in this study had any embolic 
events, gentle catheter removal from a trans-septal sheath and 
repeated saline flushing at every catheter exchange is strongly 
recommended. Although the UG-ST method is limited with 
respect to the lack of differential pacing to confirm bidirec-
tional blocks after LA linear ablation, it may also be utilized 
for complex fractionated atrial electrogram-guided ablation 
and rotor ablation in patients with persistent AF.
Several limitations of the present study should be considered. 
First, because the study questionnaire was designed to evalu-
ate discomfort within 24 hours of the AF ablation procedure, 
we did not assess pain after discharge. Second, rates of groin 
complications may also be affected by the choice of NOAC. 
However, we found no significant difference in the proportion 
of commercially available NOACs between two groups (p= 
0.433), and both groups were managed with the same activat-
ed clotting time target and post-procedural protamine deliv-
ery. Third, the two approaches for groin/transseptal puncture 
applied in this study differed with respect to two variables: sin-
gle versus double groin puncture and single versus double trans-
septal puncture. 
In conclusion, UG-ST is a feasible and safe ablation strategy 
for CPVI despite only using a single trans-septal procedure. 
Moreover, the UG-ST method reduces post-procedural dis-
comfort significantly during hemostasis, with a rate of clinical 
AF recurrence comparable to that of the conventional BG-DT 
method. 
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